NeuroTrauma Sciences
Clinical-stage biopharmaceutical company developing therapies for acute ischemic and chronic stroke.
Last updated September 27, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
NeuroTrauma Sciences (NTS) is a clinical-stage biopharmaceutical company based in Alpharetta, Georgia, in the United States. Founded in 2016, the company describes its mission as transforming the treatment of stroke, with a focus on improving the lives of stroke patients. Its lead indications are acute ischemic stroke (AIS) and chronic stroke, two areas of substantial unmet medical need where few effective therapeutic options exist. The company's lead compound is NTS-104, which it has been advancing through clinical development. According to the company, it was completing Phase 1 testing of NTS-104 in 2025. This places NTS among the small group of privately held biotechnology companies pursuing novel pharmacological approaches to stroke, a field historically dominated by thrombolytic and mechanical thrombectomy interventions rather than neuroprotective or reparative drug therapies. NTS is led by a team of industry and medical neuroscience experts. Scot Barry, MS, serves as President; he joined the company in July 2021 as Vice President of Chemistry, Manufacturing and Controls (CMC) before assuming the presidency. Barry brought more than 30 years of experience in the CDMO and biopharmaceutical industries, including work on commercial products such as Emtricitabine and Telbivudine, and prior roles at Pharm-Eco Laboratories (Johnson-Matthey), Ricerca (Olon Ricerca Biosciences), and Idenix Pharmaceuticals, where he led commercial development of the hepatitis B treatment Telbivudine and later served as Chairman of the Joint Manufacturing Committee following Novartis AG's acquisition of Idenix. As a private, venture-stage company, NTS does not disclose detailed financial information publicly. Its operations are centered in the United States, and its corporate identity is tied to the neuroscience and stroke-therapy segment of the biopharmaceutical industry. The company maintains a public web presence at neurotraumasciences.com, where it highlights its pipeline, leadership team, and clinical progress.
History
NeuroTrauma Sciences (NTS) was founded in 2016 as a clinical-stage biopharmaceutical company dedicated to improving the treatment of stroke. From its base in Alpharetta, Georgia, in the United States, the company set out to address acute ischemic stroke (AIS) and chronic stroke, two conditions with significant unmet medical need and limited effective pharmacological options. The company's development efforts have centered on its lead compound, NTS-104. By 2025, NTS reported that it was completing Phase 1 clinical testing of NTS-104, marking a key milestone in the compound's progression toward later-stage trials. This places the company in the emerging field of stroke-focused biotechnology, where most treatment advances have historically come from reperfusion strategies such as thrombolytics and mechanical thrombectomy rather than from neuroprotective or restorative drug candidates. Leadership at NTS reflects a blend of industry and medical neuroscience expertise. Scot Barry, MS, joined the company in July 2021 as Vice President of Chemistry, Manufacturing and Controls (CMC) and later became President. Barry's background spans more than 30 years in the CDMO and biopharmaceutical sectors, including work on commercial products such as Emtricitabine and Telbivudine. He held positions at Pharm-Eco Laboratories (Johnson-Matthey) and Ricerca (Olon Ricerca Biosciences), and served as VP of CMC at Idenix Pharmaceuticals, where he led commercial development of the hepatitis B treatment Telbivudine. After Novartis AG acquired Idenix, he served as Chairman of the Joint Manufacturing Committee between the two organizations. He has also consulted for pharmaceutical industry leaders on intellectual property protection, post-commercialization life cycle management, outsourcing strategy, and operational efficiency. As a privately held, clinical-stage company, NTS does not publicly report financial results or detailed corporate transactions. Its public communications emphasize its pipeline, clinical progress, and scientific leadership, and its corporate identity is closely tied to the neuroscience and stroke-therapy segment of the biopharmaceutical industry.
- 2025
Company reports completing Phase 1 clinical testing of lead compound NTS-104.
- 2021
Scot Barry, MS, joins NeuroTrauma Sciences as Vice President of Chemistry, Manufacturing and Controls (CMC).
- 2016
NeuroTrauma Sciences founded as a clinical-stage biopharmaceutical company focused on stroke.
Products and positioning
Clinical-stage biopharmaceutical company focused on transforming the treatment of stroke, targeting acute ischemic stroke and chronic stroke.
NTS-104
Recent events
NTS announces NTS Studio creative agency[3]
NTS announced the upcoming official launch of NTS Studio, its creative agency.
NeuroTrauma Sciences appoints research and development vice president[4]
Reported:
NeuroTrauma Sciences announced Todd Verdoorn's appointment as vice president of research and development.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/neurotrauma-sciences-united-states · Editorial policy · How profiles are compiled